Brokers Offer Predictions for Corcept Therapeutics Incorporated’s FY2025 Earnings (NASDAQ:CORT)

Corcept Therapeutics Incorporated (NASDAQ:CORT) – Analysts at HC Wainwright cut their FY2025 earnings per share (EPS) estimates for Corcept Therapeutics in a research note issued on Thursday, May 2nd. HC Wainwright analyst S. Ramakanth now forecasts that the biotechnology company will post earnings of $1.40 per share for the year, down from their prior forecast of $1.44. HC Wainwright currently has a “Buy” rating and a $40.00 price target on the stock. The consensus estimate for Corcept Therapeutics’ current full-year earnings is $0.97 per share.

Several other equities analysts have also issued reports on the company. StockNews.com lowered Corcept Therapeutics from a “strong-buy” rating to a “buy” rating in a research report on Friday. Truist Financial increased their price objective on shares of Corcept Therapeutics from $42.00 to $44.00 and gave the stock a “buy” rating in a research report on Thursday. Five analysts have rated the stock with a buy rating, According to data from MarketBeat, the stock currently has a consensus rating of “Buy” and an average price target of $40.10.

Corcept Therapeutics Trading Down 2.2 %

NASDAQ:CORT opened at $24.52 on Monday. The stock has a market cap of $2.55 billion, a price-to-earnings ratio of 23.13 and a beta of 0.50. The stock has a 50-day moving average price of $23.97 and a two-hundred day moving average price of $25.18. Corcept Therapeutics has a 1 year low of $20.84 and a 1 year high of $34.28.

Corcept Therapeutics (NASDAQ:CORT) last issued its earnings results on Wednesday, May 1st. The biotechnology company reported $0.25 EPS for the quarter, beating the consensus estimate of $0.21 by $0.04. The firm had revenue of $146.80 million during the quarter, compared to the consensus estimate of $141.19 million. Corcept Therapeutics had a net margin of 22.38% and a return on equity of 24.19%. The business’s quarterly revenue was up 38.9% on a year-over-year basis. During the same quarter in the prior year, the firm earned $0.14 earnings per share.

Insider Transactions at Corcept Therapeutics

In other news, CAO Joseph Douglas Lyon sold 1,000 shares of Corcept Therapeutics stock in a transaction that occurred on Friday, February 16th. The shares were sold at an average price of $26.00, for a total value of $26,000.00. Following the sale, the chief accounting officer now directly owns 6,774 shares in the company, valued at $176,124. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. In related news, CAO Joseph Douglas Lyon sold 1,000 shares of Corcept Therapeutics stock in a transaction dated Friday, February 16th. The stock was sold at an average price of $26.00, for a total value of $26,000.00. Following the sale, the chief accounting officer now owns 6,774 shares of the company’s stock, valued at $176,124. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, Director Daniel N. Swisher, Jr. sold 2,200 shares of the stock in a transaction that occurred on Friday, March 1st. The shares were sold at an average price of $23.59, for a total value of $51,898.00. The disclosure for this sale can be found here. Insiders sold 81,583 shares of company stock valued at $2,070,596 in the last ninety days. 20.50% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On Corcept Therapeutics

A number of hedge funds and other institutional investors have recently bought and sold shares of CORT. GAMMA Investing LLC lifted its position in shares of Corcept Therapeutics by 90.6% in the first quarter. GAMMA Investing LLC now owns 1,218 shares of the biotechnology company’s stock valued at $31,000 after buying an additional 579 shares during the last quarter. FNY Investment Advisers LLC bought a new stake in Corcept Therapeutics in the 4th quarter valued at $32,000. Gladius Capital Management LP acquired a new stake in Corcept Therapeutics during the 4th quarter valued at $36,000. Planned Solutions Inc. bought a new position in Corcept Therapeutics during the fourth quarter worth $45,000. Finally, FinTrust Capital Advisors LLC boosted its position in Corcept Therapeutics by 318.7% during the first quarter. FinTrust Capital Advisors LLC now owns 1,771 shares of the biotechnology company’s stock worth $45,000 after purchasing an additional 1,348 shares during the period. Institutional investors own 93.61% of the company’s stock.

About Corcept Therapeutics

Corcept Therapeutics Incorporated engages in discovery and development of drugs for the treatment of severe endocrinologic, oncologic, metabolic, and neurologic disorders in the United States. It offers Korlym tablets medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous cushing's syndrome; and who have type 2 diabetes mellitus or glucose intolerance and have failed surgery or are not candidates for surgery.